News
BTG receives US Voraxaze approval
UK-based pharmaceutical company BTG has received US Food and Drug Adminsitration (FDA) approval for its Voraxaze medication, which is used to treat patients suffering from toxic levels of methotrexate due to kidney failure. The basis of the approval...
News
AstraZeneca and Bristol-Myers Squibb diabetes drug rejected by FDA
Approval for AstraZeneca and Bristol-Myers Squibb's diabetes drug dapagliflozin has been rejected by the US Food and Drug Administration. The FDA issued the rejection in its complete response letter, stating that additional clinical data...
News
Antidepressants cause three times more falls in people with dementia
Elderly people with dementia are three times more likely to have an injurious fall if they take antidepressants, according to research published in the British Journal of Clinical Pharmacology. The association with falls can...
News
Totally drug-resistant TB found in Mumbai
A strain of tuberculosis said to be resistant to all antibiotics has been reported in India. A study released in December by Clinical Infectious Diseases documented four cases of the disease in the country,...
News
FDA calls for strictest warning on drug linked to brain infection
The US Food and Drug Administration plans to strengthen the warning label on lymphoma drug Adcetris over concerns that it may be linked to a rare, but deadly brain infection. At the time of...
News
AstraZeneca to enter into European evidence collaboration
AstraZeneca has entered into a three-year collaboration agreement with healthcare information and technology provider IMS Health. The collaboration will see both companies boost the use of real-world evidence throughout Europe in order to improve...
News
GSK responds to Argentinian court ruling over controversial vaccine trials
GlaxoSmithKline (GSK) will appeal to the Supreme Court of Argentina against a ruling issued by Judge Marcelo Aguinsky over the inadequate handling of administrative conduct during the firm's Clinical Otitis Media and Pneumonia study in 2007-08. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read